SIRT1 gene polymorphisms and risk of lung cancer

Yanbo Lv
Shuangyan Lin
Fang Peng

Department of Pathology, Zhejiang
Hospital, Hangzhou City, Zhejiang,
China

Objective: Lung cancer, which is the leading cause of cancer death worldwide, is influenced by a wide variety of environmental and genetic risk factors. The silent information regulator 1 (*SIRT1*) gene is located on the long arm of chromosome 10 (10q21.3) and has been shown to play crucial roles in lung cancer development in previous studies. In this study, we determined whether variation in the *SIRT1* gene is associated with lung cancer in Chinese population.

Methods: The case-control study comprised 246 controls and 257 non-small cell lung cancer patients, comprising 79 squamous cell carcinoma patients and 124 adenocarcinoma patients. All subjects were from Zhejiang, China. Four single-nucleotide polymorphisms of *SIRT1* gene were analyzed: rs12778366 (C/T, lies in the 5' upstream), rs3758391 (C/T, lies in the 5' upstream), rs2273773 (C/T, lies in the coding) and rs4746720 (C/T, lies in the 3' untranslated region).

Results: No significant difference of allele and genotype frequencies was observed between the different groups. Haplotype association analysis carried out on the four single-nucleotide polymorphisms within the case-control cohort also did not reveal a significant association with lung cancer ($P>0.05$).

Conclusion: The results suggest the tested *SIRT1* gene polymorphisms may not contribute to lung cancer. Further studies are warranted to demonstrate the functional roles of the *SIRT1* polymorphism in lung cancer.

Keywords: *SIRT1*, SNP, non-small cell lung cancer, adenocarcinoma, squamous cell carcinoma

Introduction

Lung cancer is the leading cause of cancer death worldwide, and non-small cell lung cancer (NSCLC) that consists mainly of squamous cell carcinoma (SCC) and adenocarcinoma (AD) accounts for nearly 80% of all lung cancer cases.¹ Thus, understanding of the mechanisms of lung carcinogenesis in the NSCLC subtypes is urgently needed.

The silent information regulator 2 (Sir2) family is a highly conserved group of genes from bacteria to humans and encodes a group of nicotinamide adenine dinucleotide (NAD⁺)-dependent histone deacetylases.² In mammalian cells, there are seven homologues (Sir2s 1–7) of yeast Sir2, termed sirtuins, which share the catalytic domain with Sir2.³ *Sirt1*, which is located in the long arm of chromosome 10 (10q21.3) and consists of nine exons and eight introns, is the closest homologue of yeast Sir2.^{4–6} Many studies have shown that *SIRT1* regulates a wide variety of cellular functions, such as mitochondrial biogenesis, autophagy, circadian rhythms, stress resistance, apoptosis, and glucose and lipid metabolism.^{7–9} *SIRT1* gene has been extensively studied, and was shown to be implicated in cancer, inflammation, obesity, diabetes, and cardiovascular and neurodegenerative diseases.^{10–12} *SIRT1* deacetylates various transcription factors

Correspondence: Fang Peng
Department of Pathology, Zhejiang
Hospital, 12 Lingyin road, Xihu District,
Hangzhou City, Zhejiang, China
Tel +86 135 8888 1606
Fax +86 571 8159 5347
Email pengfang999@139.com

that are involved in stress response, cell cycle and apoptosis, such as p53, Ku70, nuclear factor kB, FOXO and HIC1.^{13–18} Animal studies demonstrated that SIRT1 was essential to the embryonic development.^{15,19} On the other hand, accumulating evidence showed that SIRT1 was overexpressed in various types of malignant cells, and its inhibitors suppressed the growth of tumor cells.

To date, polymorphisms in *SIRT1* have been associated with several disease-related phenotypes, including diabetes, body mass index, obesity, cholesterol metabolism, energy expenditure, glucose tolerance and cardiovascular disease.²⁰ However, very little is known about the association of polymorphism of *SIRT1* and lung cancer development in the Chinese Han population. Based on the previous reports, we hypothesized that polymorphisms in *SIRT1* might also be associated with susceptibility to lung cancer. Therefore, four functional single-nucleotide polymorphisms (SNPs) were selected for further investigation of their association with lung cancer.

Patients and methods

Subject selection

We conducted a retrospective study using in-patient medical records of patients with NSCLC who were treated at Zhejiang Hospital in China. The case–control study consisted of 257 patients with NSCLC and 246 controls. The records of 257 patients with NSCLC admitted to Zhejiang Hospital between January 2010 and June 2015 were reviewed based on the following inclusion criteria: 1) patient was pathologically diagnosed with NSCLC; 2) patient displayed normal cardiac functions and 3) patient displayed normal serum glucose level. Exclusion criteria were the following: 1) patient with small cell lung cancer and 2) patient with malignant tumors except lung cancer.

All participants were provided written informed consent. Our study protocol was approved by the Ethics Committee of Zhejiang Hospital (No. 2013-k-2), and all experiments were conducted in accordance with the Declaration of Helsinki.

SNP selection and genotyping

The candidate SNPs were selected based on the relevant studies of the SNPs associated with human diseases, combined the result analyses by Haploview 4.2 software $r^2 \geq 0.8$ and the allele frequency in public database of the National Center for Biotechnology Information (a minor allele frequency ≥ 0.05) (<http://www.ncbi.nlm.nih.gov/snp/>) in *SIRT1* gene region (Gene ID: 23411). We downloaded the China Han population's SNP data of *SIRT1* gene from HapMap database (HapMap Genome Browser [phases 1, 2 and 3 merged genotypes and frequencies]). We then analyzed these data by Haploview 4.2 software. We found four TagSNPs with $r^2 \geq 0.8$ and a minor allele frequency ≥ 0.05 : rs12778366 (C/T, lies in the 5' upstream), rs3758391 (C/T, lies in the 5' upstream), rs2273773 (C/T, lies in the coding) and rs4746720 (C/T, lies in the 3' untranslated region [UTR]). Because that the four SNPs (tagSNPs) could capture all the SNPs with minor allele frequency ≥ 0.05 across the *SIRT1* gene region. We then conducted a further analysis about the four TagSNPs for their predicted functions by the online software FASTSNP (a web server that allows users to efficiently identify and prioritize high-risk SNPs according to their phenotypic risks and putative functional effects; FASTSNP is available at <http://fastsnp.ibms.sinica.edu.tw>; Table 1).

Genotyping was carried out by ligase detection reaction (LDR). The target DNA sequences were amplified using a multiplex polymerase chain reaction method (the primer and probe sequence are shown in Table 1). LDR (2 min at 95°C,

Table 1 The primer sequences and predicted functions for *SIRT1* gene polymorphisms

SNP	Location	Risk*	Predicted function*	Primer sequence (5'–3')
rs12778366	5' Upstream	Unknown–unknown (0–0)	Upstream with no known function	Sense: TAAGGCTTCTAGGACTGGAG Antisense: CTAAGGTCCTATCTACATCC
rs3758391	5' Upstream	Very low–medium (1–3)	Promoter/regulatory region	Sense: GCACACTGTGACTCCATATC Antisense: GCCATAACAAACACTGGCTC
rs2273773	Coding	Very low–very low (1–1)	Sense/synonymous	Sense: TGGGTATAGTTGCGAAGTAG Antisense: TGGACAATTCCAGCCATCTC
rs4746720	3' UTR	Unknown–unknown (0–0)	Downstream with no known function	Sense: AGTTAGCTGCCACAGTTTGT Antisense: GTACTCAAATCTGTTACGC

Note: *Analyzed by the online software FASTSNP (a web server that allows users to efficiently identify and prioritize high-risk SNPs, according to their phenotypic risks and putative functional effects).

Abbreviations: SNP, single-nucleotide polymorphism; *SIRT1*, the silent information regulator 1; UTR, untranslated region.

and 15 s at 94°C, 25s at 50°C, for 40 cycles) was proceeded in a final volume of 10 μ L, which contained 1 μ L 1 $\times$ New England Biolabs (NEB) buffer for Taq DNA Ligase (New England Biolabs, Beverly, MA, USA), 1 μ L of 2 pmol/ μ L of each common probe, 4 μ L of Multi-polymerase chain reaction product and 0.5 μ L of 2 U/ μ L Taq DNA Ligase. The fluorescent products of LDR were differentiated by ABI 377 sequencer (Perkin-Elmer, Foster City, CA, USA). The result was analyzed by GeneMapper Analysis Software 3.7 (Applied Biosystems, Foster City, CA, USA). The primer sequences are shown in the Table 1.

Statistical analysis

The χ^2 test was used to compare the distribution of the genotypes between lung cancer patients and controls using SPSS 17.0 (SPSS Inc., Chicago, IL, USA). Haploview 4.2 was used to calculate and display linkage disequilibrium (LD) values between the four SNPs. Hardy–Weinberg equilibrium test, genotype frequencies and LD were calculated using the SNPstats software (a web tool for the analysis of association studies: <http://bioinfo.iconcologia.net/SNPstats>).²¹ The odds ratio and 95% CI were calculated to evaluate the risk between genotype frequencies and lung cancer. LD between SNPs was measured by calculating r^2 values. All tests were two-sided, and a P value <0.05 was considered statistically significant.

Results

Of the four SNPs genotyped within the lung cancer cases and controls, all achieved a success rate of $\geq 85\%$, with an average success rate of 98.2% by LDR detection. A total of 257 NSCLC patients (200 men and 57 women) comprising 79 SCC patients (71 men and 8 women), 124 AD patients (77 men and 47 women) and 246 healthy individuals as controls (186 men and 60 women) were included in the study. The genotype frequencies of SNPs in all the groups did not deviate significantly from the expected values under the Hardy–Weinberg equilibrium ($P > 0.05$). LD of *SIRT1* polymorphism analysis using r^2 within the case and control samples did not reveal strong LD (Figure 1).

The genotype and allele frequencies for *SIRT1* polymorphisms in NSCLC, SCC, AD and control groups are shown in Table 2. We found no significant differences between the NSCLC cases, SCC cases, AD cases and controls for the four *SIRT1* polymorphisms when the general distribution of genotypes was compared. Haplotype (TTTC, TTCT, TCTT, CTTT) association analysis carried out on the four SNPs within the case–control cohort also did not reveal a significant association to lung cancer ($P > 0.05$, data not shown).

Figure 1 Linkage disequilibrium (r^2) plot of the silent information regulator 1 and single-nucleotide polymorphisms genotyped in this study; figures within the squares are the r^2 values expressed as a percentage.

Discussion

The *SIRT1* is located on the long arm of chromosome 10 (10q21.3). It has been shown to play crucial roles in mammalian health and disease and is often associated with the most complex physiologic processes such as metabolism, cancer and aging due to its NAD⁺-dependent deacetylase activity.²² The mammalian *SIRT1* regulates several transcription factors that control the expression of genes involved in the metabolism and endocrine signaling, such as PPAR γ , PGC1- α , UCP2, NF κ B and FOXO1 proteins, and plays important roles in glucose homeostasis and insulin secretion.^{23–25} In the human *SIRT1* gene, multiple variants have been described, several of which are associated with carotid atherosclerosis, body mass index, aging, type 2 diabetes and risk of obesity.^{26–31} However, very few *SIRT1* variants have been reported in lung cancer. Therefore, the main objective of this study was to identify the SNPs in *SIRT1* and to estimate the extent of associations between these SNPs and NSCLC.

Overexpression of SIRT1 or treating with *SIRT1* activators improves glucose homeostasis and insulin sensitivity in mice.^{22,32,33} Li et al³⁴ observed a significant association between the C.–274C>G polymorphism and growth traits in Nanyang cattle. They found that the G allele-containing construct displayed a strikingly lower promoter activity compared with the C allele by the luciferase assay system. In addition, they also found g.17379 A>G polymorphism was significantly related to body weight of 6 and 12 months old in NY population.³⁵ Kilic et al³⁶ reported that the oldest people carrying AG genotypes for rs7895833

Table 2 Association between *SIRT1* polymorphisms and NSCLC, SCC or AD

	Control (n=246), n (%)	NSCLC (n=257), n (%)	NSCLC vs control		SCC (n=79), n (%)	SCC vs control		AD (n=124), n (%)	AD vs control	
			OR (95% CI)	P-value		OR (95% CI)	P-value		OR (95% CI)	P-value
SIRT1										
rs12778366										
TT	186 (75.6)	189 (73.5)	1.00		64 (81)	1.00		87 (70.7)	1.00	
TC	56 (22.8)	61 (23.7)	1.07 (0.71–1.63)	0.66	14 (17.7)	0.76 (0.39–1.47)	0.65	31 (25.2)	1.12 (0.67–1.87)	0.32
CC	4 (1.6)	7 (2.7)	1.72 (0.50–5.98)		1 (1.3)	0.62 (0.07–5.62)		5 (4.1)	2.78 (0.72–10.73)	
rs3758391										
TT	179 (72.8)	178 (69.3)	1.00		56 (70.9)	1.00		80 (65)	1.00	
TC	62 (25.2)	72 (28)	1.17 (0.78–1.74)	0.66	21 (26.6)	1.03 (0.57–1.85)	0.98	39 (31.70)	1.43 (0.88–2.33)	0.30
CC	5 (2)	7 (2.7)	1.41 (0.44–4.52)		2 (2.5)	1.20 (0.22–6.43)		4 (3.2)	1.64 (0.42–6.36)	
rs2273773										
TT	124 (50.4)	133 (51.8)	1.00		35 (44.3)	1.00		70 (56.9)	1.00	
TC	100 (40.6)	98 (38.1)	0.91 (0.63–1.32)	0.81	35 (44.3)	1.30 (0.75–2.23)	0.6	43 (35)	0.74 (0.47–1.19)	0.45
CC	22 (8.9)	26 (10.1)	1.10 (0.59–2.05)		9 (11.4)	1.33 (1.56–3.18)		10 (8.1)	0.85 (0.38–1.910)	
rs4746720										
TT	79 (32.1)	94 (36.6)	1.00		26 (32.9)	1.00		47 (38.2)	1.00	
TC	123 (50)	124 (48.2)	0.85 (0.57–1.25)	0.50	42 (53.2)	1.13 (0.64–2.01)	0.63	58 (47.1)	0.76 (0.47–1.23)	0.45
CC	44 (17.9)	39 (15.2)	0.74 (0.44–1.26)		11 (13.9)	0.79 (0.35–1.76)		18 (14.6)	0.71 (0.37–1.38)	

Abbreviations: AD, adenocarcinoma; NSCLC, non-small cell lung cancer; OR, odds ratio; SCC, squamous cell carcinoma; *SIRT1*, the silent information regulator 1.

have the highest *SIRT1* level, suggesting an association between rs7895833 SNP and lifespan longevity. The 2827 A>G polymorphism is positioned on exon 2, leading to a histidine-to-arginine conversion. Although Izmirli et al⁶ found no statistically significant relation between the 2827 A>G at the *SIRT1* and cardiovascular disease, Peeters et al³⁷ reported that *SIRT1* rs7895833 and rs7069102 polymorphisms were associated with cardiovascular disease. Shimoyama et al³⁸ reported that the different allele frequencies in rs7895833 and rs7069102 between hemodialysis patients and controls could have an impact on the survival of Japanese hemodialysis patients.

Very little is known about the effect of polymorphism of *SIRT1* gene on lung cancer until now, despite the fact that many studies had been carried out on the association between the SNPs of *SIRT1* and human diseases. In this study, we assessed whether genetic variations in *SIRT1* are associated with NSCLC, which consists mainly of SCC and AD and accounts for nearly 80% of all lung cancer cases. According to our previous report,³⁹ the expression of *SIRT1* was significantly associated with unfavorable SCC characteristics, but not

with AD characteristics; furthermore, we compared the SNP frequencies in SCC patients vs controls and AD patients vs controls. We investigated four TagSNPs: rs12778366 (C/T, lies in the 5' upstream), rs3758391 (C/T, lies in the 5' upstream), rs2273773 (C/T, lies in the coding) and rs4746720 (C/T, lies in the 3' UTR), which could capture all the SNPs with minor allele frequency ≥ 0.05 across the *SIRT1* gene region in 257 NSCLC patients (200 men and 57 women), 79 SCC patients (71 men and 8 women), 124 AD patients (77 men and 47 women) and 246 healthy controls (186 men and 60 women). By LDR detection, we achieved a success rate of 98.2% for the four Tag-SNPs. However, no association was detected between the SNP rs3758391 and NSCLC in Chinese population, which was similar to the previous study that reported no significant relationship between the SNP rs3758391 and extreme aging in Germans.^{40,41} Although in another study, rs3758391/C was found more common than rs3758391/T ($P=0.026$) and rs3758391/CC was more common than rs3758391/CT and rs3758391/TT ($P=0.027$) in the aging subjects.⁴² The difference might be due to the different genetic background in different populations. rs4746720, which is located in the 3' UTR, was also a TagSNP of *SIRT1* gene

in Chinese Han population. Besides, Zhang et al⁴² found that rs4746720/C was more common than rs4746720/T ($P=0.022$) and rs4746720/CC was more common than rs4746720/CT and rs4746720/TT ($P=0.049$) in the aging subjects. In contrast, our study did not find rs4746720 as a significant marker for lung cancer in the case-control analysis. Figarska et al³⁰ showed an association between the SNP rs12778366 in *SIRT1* gene and long-term survival in 1390 subjects of the Vlagtwedde/Vlaardingen cohort. Rai et al⁴³ sequenced the 1.46 kb region upstream of the translation start site of the *SIRT1* gene in 1542 samples (692 type 2 diabetes patients and 850 controls) in the North Indian population and observed that rs12778366 (lies in the promoter region of *SIRT1*) was associated with SIRT1 expression. However, in our case-control study, we did not find any relationship of the rs12778366 polymorphism in the NSCLC and control groups, SCC and control groups and AD and control groups. In addition, Flachsbart et al⁴¹ studied the relationship between five SNPs (rs3758391, rs1885472, rs2273773, rs10997870 and rs2234975) in *SIRT1* gene in 1026 unrelated German long-lived individuals (mean age: 98.3 years) and found no association between *SIRT1* gene polymorphisms and exceptional human longevity. In our study, we also did not find any effect of the rs2273773 polymorphism in the NSCLC and control groups, SCC and control groups, AD and control groups.

The haplotypes (TTTC, TTCT, TCTT, CTTT) observed here are likely to represent some of the variation in the *SIRT1* genomic region in the population analyzed. In this study, we found no relationship of the haplotypes of the *SIRT1* in the NSCLC and control groups, SCC and control groups, AD and control groups.

To the best of our knowledge, this is the first report about the polymorphism of *SIRT1* and lung cancer. In our study, we found no significant association between *SIRT1* gene polymorphisms and human NSCLC, since we did not find any significant polymorphism of the *SIRT1* gene in the NSCLC and control groups, SCC and control groups, AD and control groups. The findings presented here may be due to the small number of the cases and controls, which is the main limitation of our study, due to the complex multifactorial genetic contribution to lung cancer. Expanding the sample size might be able to find a more meaningful result. Therefore, further studies with more sample size and subtle design are still necessary to delineate the functional roles of *SIRT1* polymorphism on lung cancer.

Acknowledgment

This work is supported by the Zhejiang Provincial Health Bureau Foundation (No. 2011KYA024 and No. 2013KYA004) and innovation disciplines of Zhejiang province to Xu-Jiao Chen.

Disclosure

The authors report no conflicts of interest in this work.

References

- Niklinski J, Niklinska W, Chyczewski L, Becker HD, Pluygers E. Molecular genetic abnormalities in premalignant lung lesions: biological and clinical implications. *Eur J Cancer Prev*. 2001;10(3):213–226.
- Imai S, Armstrong CM, Kaerberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. *Nature*. 2000;403(6771):795–800.
- Blander G, Guarente L. The Sir2 family of protein deacetylases. *Annu Rev Biochem*. 2004;73:417–435.
- Frye RA. Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. *Biochem Biophys Res Commun*. 1999;260(1):273–279.
- Voelter-Mahlknecht S, Mahlkecht U. Cloning, chromosomal characterization and mapping of the NAD-dependent histone deacetylases gene sirtuin 1. *Int J Mol Med*. 2006;17(1):59–67.
- Izmirli M, Goktekin O, Bacaksiz A, Uysal O, Kilic U. The effect of the SIRT1 2827 A>G polymorphism, resveratrol, exercise, age and occupation in Turkish population with cardiovascular disease. *Anatol J Cardiol*. 2015;15(2):103–106.
- Guarente L, Franklin H. Epstein lecture: sirtuins, aging, and medicine. *N Engl J Med*. 2011;364(23):2235–2244.
- Oberdoerffer P, Michan S, McVay M, et al. SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. *Cell*. 2008;135(5):907–918.
- Alcendor RR, Gao S, Zhai P, et al. Sirt1 regulates aging and resistance to oxidative stress in the heart. *Circ Res*. 2007;100(10):1512–1521.
- Horio Y, Hayashi T, Kuno A, Kunimoto R. Cellular and molecular effects of sirtuins in health and disease. *Clin Sci (Lond)*. 2011;121(5):191–203.
- Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. *Annu Rev Pathol*. 2010;5:253–295.
- Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. *Nature*. 2009;460(7255):587–591.
- Naqvi A, Hoffman TA, DeRico J, et al. A single-nucleotide variation in a p53-binding site affects nutrient-sensitive human SIRT1 expression. *Hum Mol Genet*. 2010;19(21):4123–4133.
- Cohen HY, Miller C, Bitterman KJ, et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. *Science*. 2004;305(5682):390–392.
- Cheng HL, Mostoslavsky R, Saito S, et al. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. *Proc Natl Acad Sci U S A*. 2003;100(19):10794–10799.
- Tseng RC, Lee CC, Hsu HS, Tzao C, Wang YC. Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients. *Neoplasia*. 2009;11(8):763–770.
- Yeung F, Hoberg JE, Ramsey CS, et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. *EMBO J*. 2004;23(12):2369–2380.
- Brunet A, Sweeney LB, Sturgill JF, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. *Science*. 2004;303(5666):2011–2015.
- McBurney MW, Yang X, Jardine K, et al. The mammalian SIR2alpha protein has a role in embryogenesis and gametogenesis. *Mol Cell Biol*. 2003;23(1):38–54.
- Nogueiras R, Habegger KM, Chaudhary N, et al. Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. *Physiol Rev*. 2012;92(3):1479–1514.
- Sole X, Guino E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. *Bioinformatics*. 2006;22(15):1928–1929.
- Liang F, Kume S, Koya D. SIRT1 and insulin resistance. *Nat Rev Endocrinol*. 2009;5(7):367–373.
- Kitamura YI, Kitamura T, Kruse JP, et al. FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA induction. *Cell Metab*. 2005;2(3):153–163.

24. Moynihan KA, Grimm AA, Plueger MM, et al. Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. *Cell Metab.* 2005;2(2):105–117.
25. Picard F, Kurtev M, Chung N, et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. *Nature.* 2004;429(6993):771–776.
26. Clark SJ, Falchi M, Olsson B, et al. Association of sirtuin 1 (SIRT1) gene SNPs and transcript expression levels with severe obesity. *Obesity (Silver Spring).* 2012;20(1):178–185.
27. Kedenko L, Lamina C, Kedenko I, et al. Genetic polymorphisms at SIRT1 and FOXO1 are associated with carotid atherosclerosis in the SAPHIR cohort. *BMC Med Genet.* 2014;15:112.
28. Zillikens MC, van Meurs JB, Rivadeneira F, et al. SIRT1 genetic variation is related to BMI and risk of obesity. *Diabetes.* 2009;58(12):2828–2834.
29. Dong Y, Guo T, Traurig M, et al. SIRT1 is associated with a decrease in acute insulin secretion and a sex specific increase in risk for type 2 diabetes in Pima Indians. *Mol Genet Metab.* 2011;104(4):661–665.
30. Figarska SM, Vonk JM, Boezen HM. SIRT1 polymorphism, long-term survival and glucose tolerance in the general population. *PLoS One.* 2013;8(3):e58636.
31. Zheng J, Chen LL, Xiao F, Hu X, Deng X, Li H. Three single nucleotide variants of the SIRT1 gene are associated with overweight in a Chinese population: a case control study. *Endocr J.* 2012;59(3):229–237.
32. Li Y, Xu S, Giles A, et al. Hepatic overexpression of SIRT1 in mice attenuates endoplasmic reticulum stress and insulin resistance in the liver. *FASEB J.* 2011;25(5):1664–1679.
33. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. *Cell.* 2006;127(6):1109–1122.
34. Li MX, Sun XM, Zhang LZ, et al. A novel c.-274C>G polymorphism in bovine SIRT1 gene contributes to diminished promoter activity and is associated with increased body size. *Anim Genet.* 2013;44(5):584–587.
35. Li M, Sun X, Hua L, et al. SIRT1 gene polymorphisms are associated with growth traits in Nanyang cattle. *Mol Cell Probes.* 2013;27(5–6):215–220.
36. Kilic U, Gok O, Erenberk U, et al. A remarkable age-related increase in SIRT1 protein expression against oxidative stress in elderly: SIRT1 gene variants and longevity in human. *PLoS One.* 2015;10(3):e117954.
37. Peeters AV, Beckers S, Verrijken A, et al. Association of SIRT1 gene variation with visceral obesity. *Hum Genet.* 2008;124(4):431–436.
38. Shimoyama Y, Mitsuda Y, Tsuruta Y, Suzuki K, Hamajima N, Niwa T. SIRTUIN 1 gene polymorphisms are associated with cholesterol metabolism and coronary artery calcification in Japanese hemodialysis patients. *J Ren Nutr.* 2012;22(1):114–119.
39. Lin SY, Peng F. Association of SIRT1 and HMGA1 expression in non-small cell lung cancer. *Oncol Lett.* 2016;11(1):782–788.
40. Kuningas M, Putters M, Westendorp RG, Slagboom PE, van Heemst D. SIRT1 gene, age-related diseases, and mortality: the Leiden 85-plus study. *J Gerontol A Biol Sci Med Sci.* 2007;62(9):960–965.
41. Flachsbart F, Croucher PJ, Nikolaus S, et al. Sirtuin 1 (SIRT1) sequence variation is not associated with exceptional human longevity. *Exp Gerontol.* 2006;41(1):98–102.
42. Zhang WG, Bai XJ, Chen XM. SIRT1 variants are associated with aging in a healthy Han Chinese population. *Clin Chim Acta.* 2010;411(21–22):1679–1683.
43. Rai E, Sharma S, Kaul S, et al. The interactive effect of SIRT1 promoter region polymorphism on type 2 diabetes susceptibility in the North Indian population. *PLoS One.* 2012;7(11):e48621.

Cancer Management and Research

Publish your work in this journal

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. The manuscript management system is completely online and includes

Submit your manuscript here: <https://www.dovepress.com/cancer-management-and-research-journal>

a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress